Teva Pharmaceuticals
TEVA
427 hedge funds and large institutions have $4.07B invested in Teva Pharmaceuticals in 2019 Q3 according to their latest regulatory filings, with 46 funds opening new positions, 119 increasing their positions, 145 reducing their positions, and 69 closing their positions.
4.46% less ownership
Funds ownership: 58.61% → 54.15% (-4.5%)
6% less funds holding
Funds holding: 452 → 427 (-25)
18% less repeat investments, than reductions
Existing positions increased: 119 | Existing positions reduced: 145
31% less capital invested
Capital invested by funds: $5.91B → $4.07B (-$1.84B)
33% less first-time investments, than exits
New positions opened: 46 | Existing positions closed: 69
43% less call options, than puts
Call options by funds: $219M | Put options by funds: $385M
50% less funds holding in top 10
Funds holding in top 10: 6 → 3 (-3)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
+$100M |
| 2 |
ACM
Abrams Capital Management
Boston,
Massachusetts
|
+$46M |
| 3 |
CS
Credit Suisse
Zurich,
Switzerland
|
+$28.5M |
| 4 |
CA
Commerzbank Aktiengesellschaft
Frankfurt,
Germany
|
+$23.5M |
| 5 |
MTWSIF
Mivtachim The Workers Social Insurance Fund
Tel Aviv,
Israel
|
+$15.9M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Franklin Resources
San Mateo,
California
|
-$155M |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$73M |
| 3 |
CCM
Camber Capital Management
Boston,
Massachusetts
|
-$60M |
| 4 |
AllianceBernstein
Nashville,
Tennessee
|
-$51.2M |
| 5 |
HIIFS
Harel Insurance Investments & Financial Services
Ramat Gan,
Israel
|
-$49.4M |
TEVA Hedge Fund Activity: Q3 2019 in Review
427 of the 4,560 institutional investors tracked by Wall St. Rank reported a position in Teva Pharmaceuticals (TEVA) for Q3 2019, worth a combined $4.07B — down 31% from $5.91B a quarter earlier.
Sellers outnumbered buyers: 69 funds closed out of TEVA and 46 opened new positions — a net loss of 23 holders — while 145 trimmed existing stakes and 119 added.
The largest buyer was Wellington Management Group, adding an estimated $100M. The largest seller was Franklin Resources, cutting an estimated $155M.
- 427 institutional investors held Teva Pharmaceuticals (TEVA) as of Q3 2019, down from 452 in Q2 2019.
- Funds reported $4.07B of Teva Pharmaceuticals stock for Q3 2019, down 31% quarter-over-quarter.
- 46 funds opened new Teva Pharmaceuticals positions in Q3 2019 and 69 closed out, a net change of -23 holders.
- The largest Teva Pharmaceuticals buyer in Q3 2019 was Wellington Management Group, an estimated $100M added.
- The largest Teva Pharmaceuticals seller in Q3 2019 was Franklin Resources, an estimated $155M sold.
Based on aggregated 13F filings for Q3 2019.